IMCAS, Paris, Feb. 1, 2013 (GLOBE NEWSWIRE) -- myoscience, inc. has announced the release of iovera following CE mark approval on 24 January 2013. IMCAS marks the launch of the iovera brand to medical aesthetic professionals. Developed and produced by myoscience, iovera is a revolutionary treatment for dynamic facial lines, which provides an immediately visible reduction in wrinkles without leaving any toxins or chemicals behind in the body. The treatment is based upon myoscience's platform technology, Focused Cold Therapy ™. It works by using the body's natural response to cold to temporarily relax the facial muscles that cause wrinkles.
Clint Carnell, CEO of myoscience, says, "CE approval and launch of the iovera brand at IMCAS marks a significant milestone for myoscience in paving the way to commercialize our product in Europe. iovera is an exciting advance meeting the clear need for a toxin-free treatment while expanding treatment choice."
Speaking at IMCAS, Daniel Cassuto, MD, professor of plastic surgery at the University of Catania in Milan says: "iovera is an exciting advance in medical aesthetics treatments and is a welcome addition to the physician's tool box. I know from experience that there are a significant number of patients for whom toxin treatments are not an option; iovera meets the needs of patients today."
Focused Cold Therapy™ delivers precise cold to peripheral nerve tissue. Nerves treated with this technology undergo a predictable period of dormancy, followed by complete restoration of function. iovera treats forehead lines immediately with results lasting up to 4 months. The procedure is designed for use in a minor treatments room and takes about 15 minutes. iovera will be first available in select centres of excellence before becoming more widely available across Europe throughout 2013.
For more information about iovera, visit www.myoscience.com.
About myoscience
Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy TM, the standard of care for the treatment of peripheral nerve conditions. It is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
The myoscience logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13581